The rising demand for ketamine, primarily for mental health issues, presents significant challenges regarding the provision and discreet transport within the United States. Stringent federal guidelines govern such process, demanding conformity from vendors. Furthermore, preserving patient anonymity through meticulous transport protocols and authori